The Conversation (0)
- AustraliaNorth AmericaWorld
Investing News NetworkYour trusted source for investing success
Top Stocks
Top Resource Stocks
Top Tech Stocks
Top Life Science Stocks
Trending
Trending Articles
Trending Press Releases
Trending Companies
Trending Reports
Resource
Popular Lists
Investing Ideas
Outlook Reports
- Lithium Outlook
- Oil and Gas Outlook
- Gold Outlook Report
- Uranium Outlook
- Rare Earths Outlook
- All Outlook Reports
Investing Guides
Tech
Popular Lists
- Top Generative AI Stocks
- Top EV Stocks
- Biggest AI Companies
- Biggest Blockchain Stocks
- Biggest Cryptocurrency-mining Stocks
- Biggest Cybersecurity Companies
- Biggest Robotics Companies
- Biggest Social Media Companies
- Biggest Technology ETFs
- Artificial Intellgience ETFs
- Robotics ETFs
- Canadian Cryptocurrency ETFs
Investing Ideas
Outlook Reports
- Artificial Intelligence Outlook
- EV Outlook
- Cleantech Outlook
- Crypto Outlook
- Tech Outlook
- All Market Outlook Reports
Investing Guides
Life Science
Popular Lists
- Cannabis Weekly Round-Up
- Top Alzheimer's Treatment Stocks
- Top Biotech Stocks
- Top Plant-based Food Stocks
- Biggest Cannabis Stocks
- Biggest Pharma Stocks
- Longevity Stocks to Watch
- Psychedelics Stocks to Watch
- Top Cobalt Stocks
- Small Biotech ETFs to Watch
- Top Life Science ETFs
- Biggest Pharmaceutical ETFs
Outlook Reports
- Life Science Outlook
- Biotech Outlook
- Cannabis Outlook
- Pharma Outlook
- Psychedelics Outlook
- All Market Outlook Reports
Investing Guides
Kane Biotech released their financial results for the first quarter of 2017.
Kane Biotech (TSXV:KNE) released their financial results for the first quarter of 2017.
As quoted in the press release:
Highlights:
- Total Revenue during the quarter ended March 31, 2017 was $784,900, an increase of 952% compared to $74,619 for the quarter ended December 31, 2016 and an increase of 630% compared to $107,505 for the quarter ended March 31, 2016;
- License & Royalty Revenue was $670,725 during the quarter ended March 31, 2017 compared to $0 for the quarter ended December 31, 2016 and $70,488 (License Option) for the quarter ended March 31, 2016;
- Product Revenue was $114,175 during the quarter ended March 31, 2017, an increase of 53% compared to $74,619 for the quarter ended December 31, 2016 and an increase of 208% compared to $37,017 for the quarter ended March 31, 2016;
- Gross Profit % of StrixNB and bluestem product sales were 68% during the quarter ended March 31, 2017, an increase of 58% compared to 43% for the quarter ended December 31, 2016 and an increase of 45% compared to 47% for the quarter ended March 31, 2016;
- Loss for the quarter ended March 31, 2017 was $237,692 a reduction of 52% compared to $500,576 for the quarter ended December 31, 2016 and a reduction of 79% compared to $581,358 for the quarter ended March 31, 2016;
Click here to read the full press release.
Source: www.marketwired.com
Latest News
Investing News Network websites or approved third-party tools use cookies. Please refer to the cookie policy for collected data, privacy and GDPR compliance. By continuing to browse the site, you agree to our use of cookies.